{"analyses":[{"ciLowerLimit":"0.91","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"7.24","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.076","paramType":"Odds Ratio (OR)","paramValue":"2.56","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"4.12","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"25.77","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","paramType":"Odds Ratio (OR)","paramValue":"10.30","statisticalMethod":"Regression, Logistic"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.9","upperLimit":"10.0","value":"4.5"},{"groupId":"OG001","lowerLimit":"6.7","upperLimit":"19.1","value":"11.5"},{"groupId":"OG002","lowerLimit":"27.9","upperLimit":"42.4","value":"34.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"112"},{"groupId":"OG001","value":"104"},{"groupId":"OG002","value":"161"}],"units":"Participants"}],"description":"ClinRO is a clinician reported assessment which measures a participant's EB hair loss. It is comprised of 4 category response options: 0 = EB have full coverage and no areas of hair loss; 1 = There are minimal gaps in EB hair and distribution is even; 2 = There are significant gaps in EB hair or distribution is not even; 3 = No notable EB.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received two placebo tablets matched to baricitinib, administered orally QD to maintain the blind.","id":"OG000","title":"Placebo"},{"description":"Participants received one 2 mg Baricitinib tablet administered orally QD and one placebo tablet administered orally QD to maintain the blind.","id":"OG001","title":"2 mg Baricitinib"},{"description":"Participants received one 4 mg Baricitinib tablet and one placebo tablet administered orally QD to maintain the blind.","id":"OG002","title":"4 mg Baricitinib"}],"paramType":"NUMBER","populationDescription":"All randomized participants with baseline ClinRO measure for EB hair loss ≥ 2 and who had evaluable data for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Week 36","title":"Percentage of Participants Achieving Clinician-Reported Outcome (ClinRO) Measure for Eyebrow (EB) Hair Loss 0 or 1 With ≥2-point Improvement From Baseline (Among Participants With ClinRO Measure for EB Hair Loss ≥2 at Baseline)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}